2025 - 2026 LEGISLATURE
LRB-2504/1
CMH:emw
April 23, 2025 - Introduced by Representatives Moses, Knodl, Melotik, Murphy, O'Connor, Steffen, Clancy, Fitzgerald, Madison, Miresse, Ortiz-Velez, Palmeri, Sinicki, Stubbs, Subeck and J. Jacobson, cosponsored by Senators Cabral-Guevara, Hesselbein, Ratcliff and Spreitzer. Referred to Committee on Rules.
AJR32,1,2
1Relating to: designating the first full week in May as Tardive Dyskinesia
2Awareness Week. AJR32,1,53Whereas, serious mental illnesses like bipolar disorder, major depressive 4disorder, and schizophrenia often require treatment with antipsychotic medications 5for effective management, and antipsychotic prescribing rates continue to rise; and AJR32,1,96Whereas, while prolonged antipsychotic use may be essential for the 7treatment of certain conditions, it is associated with tardive dyskinesia (TD), a 8condition marked by uncontrollable, abnormal, and repetitive movements of the 9face, torso, limbs, or extremities; and AJR32,1,1310Whereas, people at higher risk of TD include those older than 55 years; Black 11individuals; women; individuals with mood or substance use disorders, intellectual 12disabilities, or central nervous system injuries; and those with high cumulative 13antipsychotic exposure; and AJR32,2,314Whereas, approximately 60 percent of the estimated 800,000 U.S. adults
1living with TD remain undiagnosed, and even mild TD symptoms can be 2stigmatizing and impair physical, social, and emotional well-being, underscoring 3the urgency of early screening, detection, and intervention; and AJR32,2,84Whereas, the American Psychiatric Association recommends routine TD 5screening in their clinical guidelines for antipsychotic treatment, and individuals 6treated with antipsychotics or experiencing abnormal movements should consult 7their health care providers to assess TD risk, receive TD screenings, and determine 8appropriate treatment together; and AJR32,2,109Whereas, FDA-approved treatments for TD can provide options for symptom 10management and improved quality of life for many individuals living with TD; and AJR32,2,1411Whereas, the Wisconsin Legislature can encourage TD screening education 12and awareness for health care providers, patients, and care partners to help ensure 13patients prescribed antipsychotics receive care and support that aligns with clinical 14best practice, including regular TD screenings; now, therefore, be it AJR32,2,2015Resolved by the assembly, the senate concurring, That the Wisconsin 16Legislature designates the first full week in May as Tardive Dyskinesia Awareness 17Week, underscores the importance of early detection and intervention to improve 18outcomes for people living with mental health conditions and prescribed 19antipsychotics, and supports efforts to raise awareness about the causes and 20symptoms of TD and the importance of routine TD screening.
